ALSUntangled #64: butyrates.
ALS
alternative therapy
butyrate
gut microbiome
neuroinflammation
Journal
Amyotrophic lateral sclerosis & frontotemporal degeneration
ISSN: 2167-9223
Titre abrégé: Amyotroph Lateral Scler Frontotemporal Degener
Pays: England
ID NLM: 101587185
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
pubmed:
1
3
2022
medline:
16
11
2022
entrez:
28
2
2022
Statut:
ppublish
Résumé
ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review butyrate and its different chemical forms (butyrates). Butyrates have plausible mechanisms for slowing ALS progression and positive pre-clinical studies. One trial suggests that sodium phenylbutyrate (NaPB) in combination with Tauroursodeoxycholic acid (TUDCA) can slow ALS progression and prolong survival, but the specific contribution of NaPB toward this effect is unclear. Butyrates appear reasonably safe for use in humans. Based on the above information, we support a trial of a butyrate in PALS, but we cannot yet recommend one as a treatment.
Identifiants
pubmed: 35225121
doi: 10.1080/21678421.2022.2045323
doi:
Substances chimiques
Butyrates
0
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM